Skip to main content

Table 1 Differences between VAD-chemosensitive (CS) and less VAD-chemosensitive (LCS) patients

From: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

  CS [%] LCS [%] P-value
Gender    0.99
   Male 7 [63.6] 10 [71.4]  
   female 4 [36.4] 4 [28.6]  
Age (median) 49 55 0.217
paraprotein subtype    0.07
   G 3 [27.3] 9 [64.3]  
   A 1 [9.1] 3 [21.4]  
   D 2 [18.2] 0 [0]  
   LC 5 [45.5] 2 [14.3]  
ISS stage    0.69
   I & II 7 [63.6] 7 [50]  
   III 4 [36.4] 7 [50]  
≥VGPR after induction    0.227
   No 3 [27.3] 8 [57.1]  
   Yes 8 [72.7] 6 [42.9]  
≥VGPR after ABMT    0.03
   No 1 [9.1] 7 [50.0]  
   Yes 10 [90.9] 7 [50.0]  
Oligoclonal reconstitution    0.434
   Yes 5 [45.5] 4 [28.6]  
   no 6 [54.5] 10 [71.4]  
DAPK methylation    0.216
   methylated 3 [27.3] 1 [7.1]  
   unmethylated 6 [54.5] 12 [85.7]  
   unknown 2 [18.2] 1 [7.1]1  
  1. G: IgG; A: IgA; D: IgD; LC: light chain myeloma; DS: Durie-Salmon stage; ISS: International staging system; VGPR: >90% reduction in paraprotein level